Phase 4 N=108 Antibiotic Resistance In Eye Surgeries
Antibiotic Resistance · Ocular Surface Microbiome · Gut Resistome
Primary: Antimicrobial Resistance (AMR) of Conjunctiva at 1 Week — 0; 0; 0 reads per million reads — p=1
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=33 Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate
Phase 4 N=248 Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso
Child Development
Primary: Simpson's Index of Diversity (Alpha Diversity) in Intestinal Microbiome — 10.2; 8.8; 9.7; 9.6 Index score
N/A N=4 Improving Antimicrobial-Prescribing in Emergency Departments
Anti-Bacterial Agents · Respiratory Tract Infections
Primary: Percentage of Patient-visits Prescribed an Antimicrobial at Their ED Visit — 21.2; 20.9; 19.1; 21.6 percentage of visits prescribed an abx — p=0.35
Phase 2 N=19 Topical Antibiotics in Chronic Rhinosinusitis
Chronic Rhinosinusitis (Diagnosis)
Primary: Subjects Who Developed Antibiotic Resistance Organisms — 0; 0; 1; 0 Participants
N/A N=120 Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics
Bacterial Resistance
Primary: Number of Participants With Resistance of Ocular Flora to Commonly Used Post-injection Prophylactic Antibiotics — 10; 6 Participants
N/A N=203 Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
Complicated Intra-Abdominal Infection
Primary: Duration of Hospitalization — 14.1 Days
N/A N=20 Healthy Patients & Effect of Antibiotics
Microbiota · Anti-bacterial Agents
Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants
N/A N=2,140 Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance
Methicillin-resistant Staphylococcus Aureus
Primary: Time to MRSA Infection — 67; 98; 68; 98 Participants — p=0.026
N/A N=51 Comparison of Two Rescue Therapies for Helicobacter Pylori Infection
Helicobacter Pylori Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 13; 21 participants
Phase 2 N=98 Antibiotic "Dysbiosis" in Preterm Infants
Enterocolitis, Necrotizing · Bacteremia · Bronchopulmonary Dysplasia
Primary: Number of Events of Composite Morbidities and Mortality, Including Necrotizing Enterocolitis (NEC), Late Onset Sepsis (LOS), Bronchopulmonary Dysplasia (BPD) and Death…
N/A N=525 Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists
Urologic Diseases · Antibacterial Drug Adverse Reaction
Primary: Percentage of Cases Who Received Excessive Post-procedural Antimicrobials — 216; 644 Participants — p=0.004
Phase 1 N=7 Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization
Antibiotic Resistant Strain
Primary: Number of Participants With Adverse Events (NIH Grade ≥2) at Day 7 After Randomization — 4; 0 Participants
Phase 4 N=103 The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant Bacteria
Infectious Disease of Digestive Tract
Primary: Number of Participants With Combination of Gastrointestinal Tract Colonization With Multi-drug Resistant Gram-negative Bacteria, C. Difficile and VRE — 8; 8 Participants
Phase 4 N=57 Effects of Antibiotic Prophylaxis on Recurrent UTI in Children
Urinary Tract Infection · Recurrent Urinary Tract Infection
Primary: Changes to the Urinary Microbiota — 3; 2; 1 participants
N/A N=2,300 An Educational Intervention to Improve the Use of Antibiotics in Portuguese Health Professional
Antibiotics Misuse
Primary: Change From Baseline Antibiotic Consumption at 18 Months, in Primary Care — 1.71; 2.01 PID-number of packages per 1000 inhabit
N/A N=248 Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study)
Acute Respiratory Infections (ARIs)
Primary: Inappropriate Antibiotic Prescribing Rate for Qualifying Acute Respiratory Infection Diagnoses — 0.20; 0.19; 0.08; 0.09 proportion of visits
Phase 4 N=924 Clarithromycin Resistant Tailored Therapy
Peptic Ulcer · Helicobacter Pylori Infection
Primary: Helicobacter Pylori Eradication Rate — 75.9; 91.2; 79.1 percentage of participants
Phase 3 N=2,265 Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
Staphylococcal Infection
Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants
N/A N=110 Restricted Reporting for Positive Urine Cultures
Bacteriuria · Urinary Tract Infection
Primary: The Number of Patients Receiving Appropriate Treatment — 44; 29 Participants
N/A N=219 The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
Helicobacter Infection
Primary: Number of Participants in Each Arm/Group With Successful H. Pylori Eradication — 67; 63; 36 participants
Phase 4 N=864,493 Azithromycin for Child Survival in Niger: Mortality and Resistance Trial
Mortality · Resistance Bacterial · Child, Only
Primary: All-cause Mortality (1-59 Months Old) — 13.8; 11.9; 13.9 deaths per 1,000 person-years
Phase 4 N=42 Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea
Neisseria Gonorrhoeae
Primary: Macrolide Resistance Determinants — 110.3; 167.53 normalized determinants/million reads — p=0.1026
N/A N=271 Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit
Sepsis · Procalcitonin · Antimicrobial Stewardship
Primary: Days of Antibiotic Therapy in the First 14 Days Following Randomization — 7.6; 6.6 days
N/A N=8 Dissemination and Implementation of a Videoconference Antimicrobial Stewardship Team
Common Infections · Urinary Tract Infections · Pneumonia
Primary: Days of Antibiotic Therapy Per 1000 Days of Care — 710; 744 Days of Antibiotic Therapy/1000 Bed Days
Phase 3 N=259 Antibiotic Safety (SCAMP)
Complicated Intra Abdominal Infections
Primary: Death — 5; 5; 7; 1 Participants
Phase 4 N=510 Antibiotic Prophylaxis for Transrectal Prostate Biopsy
Infection
Primary: Number of Participants With Post-biopsy Infection. — 6; 3 participants — p=<0.05
N/A N=681,739 Short- and Long-Term Effects of Antibiotics on Childhood Growth
Obesity
Primary: Body Mass Index Z-score Difference at 48-72 Months, Exposed vs. No Antibiotics Less Than 24 Months — 0.04; 0.06; 0.04; 0.07 BMI z-score units
Phase 3 N=32 Aztreonam for Pharyngeal Gonorrhea
Gonorrhea of Pharynx · Gonorrhea
Primary: Treatment Efficacy of Pharyngeal Gonorrhea as Defined as the Proportion of Study Participants With Positive Pharyngeal Gonorrhea Culture at of Enrollment Whose Test of…
Phase 3 N=333 Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Complicated Urinary Tract Infection · Complicated Intra-abdominal Infection
Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant